Apogee Doses First Patient In Phase 2 Atopic Dermatitis Trial Of APG777 For The Treatment Of Atopic Dermatitis And Other Inflammatory Diseases
Portfolio Pulse from Benzinga Newsdesk
Apogee Therapeutics, Inc. (NASDAQ: APGE) has dosed the first patient in its Phase 2 trial of APG777 for atopic dermatitis. Interim data from the Phase 1 study exceeded expectations, showing a half-life of 75 days. Phase 2 proof-of-concept data is expected in the second half of 2025, with plans for further trials in asthma and other indications.
May 15, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apogee Therapeutics has initiated dosing in its Phase 2 trial of APG777 for atopic dermatitis. Phase 1 data exceeded expectations, showing a half-life of 75 days. Proof-of-concept data is expected in the second half of 2025, with further trials planned for asthma and other indications.
The initiation of the Phase 2 trial and the positive interim data from the Phase 1 study are significant milestones for Apogee Therapeutics. These developments suggest potential efficacy and a strong safety profile for APG777, which could drive investor optimism and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100